Alimera Sciences, Inc. (Nasdaq: ALIM) spotted trading -28.51% off 52-week high price. On the other end, the stock has been noted 20.46% away from the low price over the last 52-weeks. The stock changed 0.87% to recent value of $0.87. The stock transacted 49832 shares during most recent day however it has an average volume of 90.92K shares. The company has 70.57M of outstanding shares and 70.01M shares were floated in the market.
Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), a leader in the commercialization and development of prescription ophthalmology treatments for the management of retinal diseases, reported the appointment of John Snisarenko to its Board of Directors. Mr. Snisarenko has more than 30 years of commercial experience in the pharmaceutical industry, including major retina and ophthalmology businesses.
Rick Eiswirth, Alimera’s President and Chief Executive Officer said “John’s commercial experience in ophthalmology and other successful pharmaceutical products makes him a great addition to our Board of Directors and a great resource to help me guide Alimera into the future,”. “I look forward to his perspective and advisement, and welcome John to our Board.”
Mr. Snisarenko added, “ILUVIEN® brings to the table unique and impactful benefits for treating both diabetic macular edema and non-infectious posterior uveitis. I am very pleased to join Alimera’s Board of Directors at this exciting time as the Company pursues its strategy to become a leader in the treatment of retinal diseases.”
Mr. Snisarenko joined Shire (now Takeda) in 2017 as Group Vice President and Head of its ophthalmic business. During that time, he led a large, multidisciplinary team in the launch of Shire’s first ophthalmic therapeutic, Xiidra®, for treatment of dry eye. He also served as a member of the commercial leadership team at Shire and, as well, has played a key role in the divestiture of the ophthalmic business to Novartis Pharma.
Its earnings per share (EPS) expected to touch remained 175.30% for this year . ALIM has a gross margin of 90.00% and an operating margin of -12.70% while its profit margin remained 53.70% for the last 12 months.
According to the most recent quarter its current ratio was 3.3 that represents company’s ability to meet its current financial obligations. The price moved ahead of -3.36% from the mean of 20 days, -4.63% from mean of 50 days SMA and performed -10.70% from mean of 200 days price. Company’s performance for the week was -1.70%, -5.98% for month and YTD performance remained 20.46%.
Robert Winter – Category – Hot Stocks
Robert Winter studied a business degree majoring in finance and security analysis. He has a deep understanding of both technical and fundamental forms of analysis, he deeply believes that it makes a lot more sense for average investors to understand fundamental analysis, which he believes anyone can learn. Robert Winter has over 10 years of experience as a professional journalist, writer and an editor. He holds a bachelor’s degree in International Business from University of Melbourne. He writes articles about hot stocks, dividend growth investing, options trading, investment decisions, stock selection, portfolio management, and passive income generation. Robert primarily reports on Hot Stocks category.
Email Contact: [email protected]
Address: 5353 12th Avenue North, Saint Petersburg, FL 33710, USA
Zip Code: 33710
Phone Number: 727-585-5160